Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Combined PD-L1 and TIM-3 blockade improves the expansion of fit human CD8+ antigen-specific T cells for adoptive immunotherapy

Shirin Lak, View ORCID ProfileValérie Janelle, Anissa Djedid, Gabrielle Boudreau, Ann Brasey, Véronique Lisi, Cédric Carli, Lambert Busque, Vincent-Philippe Lavallée, Jean-Sébastien Delisle
doi: https://doi.org/10.1101/2021.08.30.21262835
Shirin Lak
1Centre de recherche de l’Hôpital Maisonneuve-Rosemont, Montréal, Qc, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Valérie Janelle
1Centre de recherche de l’Hôpital Maisonneuve-Rosemont, Montréal, Qc, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Valérie Janelle
Anissa Djedid
2Centre de recherche du CHU Sainte-Justine, Montréal, Qc, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gabrielle Boudreau
1Centre de recherche de l’Hôpital Maisonneuve-Rosemont, Montréal, Qc, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ann Brasey
1Centre de recherche de l’Hôpital Maisonneuve-Rosemont, Montréal, Qc, Canada
3Biomarker Unit, Centre C3i, Montréal, Qc, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Véronique Lisi
2Centre de recherche du CHU Sainte-Justine, Montréal, Qc, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cédric Carli
1Centre de recherche de l’Hôpital Maisonneuve-Rosemont, Montréal, Qc, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lambert Busque
1Centre de recherche de l’Hôpital Maisonneuve-Rosemont, Montréal, Qc, Canada
3Biomarker Unit, Centre C3i, Montréal, Qc, Canada
4Department of Medicine, Université de Montréal, Montréal, Qc, Canada
5Hematology-Oncology and Cell therapy Division, Hôpital Maisonneuve-Rosemont, Montréal, Qc, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincent-Philippe Lavallée
2Centre de recherche du CHU Sainte-Justine, Montréal, Qc, Canada
6Department of Pediatrics, Université de Montréal, Montréal, Qc, Canada
7Hematology-Oncology Division, CHU Sainte-Justine CHU Sainte-Justine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Sébastien Delisle
1Centre de recherche de l’Hôpital Maisonneuve-Rosemont, Montréal, Qc, Canada
4Department of Medicine, Université de Montréal, Montréal, Qc, Canada
5Hematology-Oncology and Cell therapy Division, Hôpital Maisonneuve-Rosemont, Montréal, Qc, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: js.delisle@umontreal.ca
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background The stimulation and expansion of antigen-specific T cells ex vivo enables the targeting of a multitude of cancer antigens. However, clinical scale T-cell expansion from rare precursors requires repeated stimulations ex vivo leading to T-cell terminal effector differentiation and exhaustion that adversely impact therapeutic potential. We leveraged immune checkpoint blockade relevant to antigen-specific CD8+ human T cells to improve the expansion and function of T cells targeting clinically relevant antigens.

Methods A clinically-compliant protocol relying on peptide-pulsed monocyte-derived dendritic cells and cytokines was used to expand antigen-specific CD8+ targeting the oncogenic Epstein-Barr virus (EBV) and the tumor associated antigen (TAA) Wilms Tumor 1 (WT1) protein. The effects of antibody-mediated blockade of immune checkpoints applied to the cultures (T-cell expansion, phenotypes and function) were assessed at various time points. Genomic studies including single cell RNA (scRNA) sequencing and T-cell receptor sequencing were performed on EBV-specific T cells to inform about the impact of immune checkpoint blockade on the clonal distribution and gene expression of the expanded T cells.

Results Several immune checkpoints were expressed early by ex vivo expanded antigen-specific CD8+ T cells, including PD-1 and TIM-3 with co-expression matching evidence of T-cell dysfunction as the cultures progressed. The introduction of anti-PD-L1 (expressed by the dendritic cells) and anti-TIM-3 antibodies in combination (but not individually) to the culture led to markedly improved antigen-specific T-cell expansion based on cell counts, fluorescent multimer staining and functional tests. This was not associated with evidence of T-cell dysfunction when compared to T cells expanded without immune checkpoint blockade. Genomics studies largely confirmed these results, showing that double blockade does not impart specific transcriptional programs or patterns on TCR repertoires. However, our data indicate that combined blockade may nonetheless alter gene expression in a minority of clonotypes and have donor-specific impacts.

Conclusions The manufacturing of antigen-specific CD8+ T cells can be improved in terms of yield and functionality using blockade of TIM-3 and the PD-L1/PD-1 axis in combination. Overcoming the deleterious effects of multiple antigenic stimulations through PD-L1/TIM-3 blockade is a readily applicable approach for several adoptive-immunotherapy strategies.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was funded by the Leukemia/Lymphoma Society of Canada (grants #622735 and #430053) to JSD.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All donors provided written informed consent, and all the experiments were approved by the Hema-Quebec and Hopital Maisonneuve-Rosemont Research Ethics Committees.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Declarations

  • Ethics approval and consent to participate. Informed consent was obtained from all cell donors as detailed in the Method section.

  • Consent for publication. All authors have reviewed the final version and agreed with the submission. The corresponding author agrees to pay the publication charges.

  • Availability of data and material. As detailed in the Methods section, the genomic data have been deposited for public access and the authors agree to share protocols. All materials used are commercially available.

  • Competing interest. The authors have no relevant conflict of interest to disclose.

  • Funding. This work was funded by the Leukemia/Lymphoma Society of Canada (grants #622735 and #430053) to JSD.

Data Availability

The data can be found in the Gene Expression Omnibus (GSE182537 and GSE181682).

  • List of Abbreviations

    ACT
    Adoptive Cell Therapy
    APC
    Antigen Presenting Cell
    CCR7
    C-C chemokine receptor type 7
    CD
    Cluster of differentiation
    CDR
    Complementarity Determining Region
    CTLA-4
    Cytotoxic T-lymphocyte-associated protein 4
    CTLs
    Cytotoxic T-lymphocytes
    CTV
    Cell Trace Violet
    CTY
    Cell Trace Yellow
    DC
    Dendritic Cell
    DMSO
    Dimethylsulfoxide
    EBV
    Epstein-Barr virus
    ELISPOT
    Enzyme-linked immune absorbent spot
    FBS
    Fetal Bovine Serum
    FOXP3
    Forkhead Box P3
    Gal-9
    Galectin-9
    GM-CSF
    Granulocyte-Macrophage Colony-Stimulating Factor
    GrzB
    GranzymeB
    HLA
    Human Leukocyte Antigen
    IFN
    Interferon
    IL
    Interleukin
    KLRG1
    Killer cell Lectin-like Receptor G1
    LAG-3
    Lymphocyte-Activation Gene 3
    LRSC
    Leukocyte Reduction System Chamber
    mAB
    Monoclonal Antibody
    MHC
    Major Histocompatibility Complex
    NGS
    Next-generation Sequencing
    PBMC
    Peripheral Blood Mononuclear Cell
    PBS
    Phosphate-buffered saline
    PD-1
    Programmed Cell Death-1
    PD-L1
    Programmed Death Ligand-1
    PGE2
    Prostaglandin E2
    PHA
    T-cell mitogen phytohemagglutinin
    PMA
    Phorbol 12-myristate 13-acetate
    RT
    Room Temperature
    sc-RNA
    Single Cell RNA
    TAA
    Tumor-Associated Antigen
    Tcm
    Central Memory T cell
    TCR
    T-cell Receptor
    Teff
    Effector T cell
    Tem
    Effector Memory T cell
    TIM-3
    T-cell Immunoglobulin and Mucin-domain Containing-3
    TMB
    3,3′,5,5′-Tetramethylbenzidine
    TNF
    Tumor Necrosis Factor
    TSA
    Tumor-Specific Antigen
    WT1
    Wilms’ tumor suppressor gene1
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
    Back to top
    PreviousNext
    Posted October 10, 2021.
    Download PDF

    Supplementary Material

    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Combined PD-L1 and TIM-3 blockade improves the expansion of fit human CD8+ antigen-specific T cells for adoptive immunotherapy
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Combined PD-L1 and TIM-3 blockade improves the expansion of fit human CD8+ antigen-specific T cells for adoptive immunotherapy
    Shirin Lak, Valérie Janelle, Anissa Djedid, Gabrielle Boudreau, Ann Brasey, Véronique Lisi, Cédric Carli, Lambert Busque, Vincent-Philippe Lavallée, Jean-Sébastien Delisle
    medRxiv 2021.08.30.21262835; doi: https://doi.org/10.1101/2021.08.30.21262835
    Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
    Citation Tools
    Combined PD-L1 and TIM-3 blockade improves the expansion of fit human CD8+ antigen-specific T cells for adoptive immunotherapy
    Shirin Lak, Valérie Janelle, Anissa Djedid, Gabrielle Boudreau, Ann Brasey, Véronique Lisi, Cédric Carli, Lambert Busque, Vincent-Philippe Lavallée, Jean-Sébastien Delisle
    medRxiv 2021.08.30.21262835; doi: https://doi.org/10.1101/2021.08.30.21262835

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Hematology
    Subject Areas
    All Articles
    • Addiction Medicine (216)
    • Allergy and Immunology (496)
    • Anesthesia (106)
    • Cardiovascular Medicine (1110)
    • Dentistry and Oral Medicine (196)
    • Dermatology (141)
    • Emergency Medicine (275)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (505)
    • Epidemiology (9796)
    • Forensic Medicine (5)
    • Gastroenterology (481)
    • Genetic and Genomic Medicine (2327)
    • Geriatric Medicine (223)
    • Health Economics (463)
    • Health Informatics (1567)
    • Health Policy (737)
    • Health Systems and Quality Improvement (608)
    • Hematology (238)
    • HIV/AIDS (508)
    • Infectious Diseases (except HIV/AIDS) (11669)
    • Intensive Care and Critical Care Medicine (617)
    • Medical Education (240)
    • Medical Ethics (67)
    • Nephrology (258)
    • Neurology (2154)
    • Nursing (134)
    • Nutrition (340)
    • Obstetrics and Gynecology (427)
    • Occupational and Environmental Health (519)
    • Oncology (1185)
    • Ophthalmology (366)
    • Orthopedics (129)
    • Otolaryngology (221)
    • Pain Medicine (148)
    • Palliative Medicine (50)
    • Pathology (314)
    • Pediatrics (699)
    • Pharmacology and Therapeutics (303)
    • Primary Care Research (268)
    • Psychiatry and Clinical Psychology (2195)
    • Public and Global Health (4685)
    • Radiology and Imaging (786)
    • Rehabilitation Medicine and Physical Therapy (458)
    • Respiratory Medicine (625)
    • Rheumatology (276)
    • Sexual and Reproductive Health (226)
    • Sports Medicine (212)
    • Surgery (252)
    • Toxicology (43)
    • Transplantation (120)
    • Urology (94)